Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB26FD1BD
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,679
Award facts
- Contract value 100% obligated
- $5,678.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $5,678.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injector units. This delivery order, issued on October 23, 2025, with an ultimate completion date of October 24, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a critical supplier within the Defense Logistics Agency's pharmaceutical supply chain, leveraging its small business status to distribute a comprehensive range of pharmaceutical products and medical consumables to Department of Defense facilities.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic pharmaceuticals, biologics, and medical consumables to support Department of Defense medical supply needs globally. Nucala, an immunosuppressant biologic agent, represents one of the specialized pharmaceutical products within DMS Pharmaceutical Group's extensive portfolio supplied to military healthcare operations.
Quick answers
Who was awarded contract SPE2DB26FD1BD?
SPE2DB26FD1BD was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FD1BD worth?
The government has obligated $5,679 on SPE2DB26FD1BD.
Is contract SPE2DB26FD1BD an order under another contract?
Yes. SPE2DB26FD1BD is a delivery order under SPE2DB20D9226, an indefinite delivery contract.
Was contract SPE2DB26FD1BD competed?
The extent of competition for SPE2DB26FD1BD was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award